Labcorp to buy Opko unit’s cancer test assets for up to $225M
Labcorp will acquire the oncology diagnostics operations from BioReference Health as part of a push to expand in high-growth testing areas.
Labcorp to acquire select oncology testing assets for up to $225M
The independent laboratory company has entered an agreement to acquire BioReference Health's oncology diagnostic services.
Labcorp to Buy Some OPKO BioReference Assets for Up to $225 Million
Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for BioReference's laboratory testing businesses, which is focused on oncology and oncology-related clinical testing services across the U.S.
Opko Health to sell more assets to Labcorp for $225 million
The sale comes after the Miami company agreed to pay $704,349 to settle allegations that it billed the federal government for unnecessary blood tests.
Labcorp to acquire certain assets of Opko Health’s BioReference Health
Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp to Acquire Select Assets of BioReference Health
Labcorp has entered into an agreement to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
Labcorp pays $225 million for BioReference's oncology testing lines in latest acquisition
Labcorp continues string of acquisitions with a deal adding BioReference oncology services in $225 million deal. Burlington-based Labcorp is investing almost a quarter of a billion dollars to add oncology testing services in its most recent acquisition.
Hosted on MSN1mon
BioReference faces $704,349 fine for medically unnecessary blood tests
BioReference Health LLC, formerly known as BioReference Laboratories Inc. (BioReference) and OPKO Health Inc. (OPKO), face a $704,349 government fine for medically unnecessary blood tests.
Truist remains bullish on Labcorp after ‘another nice strategic acquisition’
Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an ...
Labcorp, Opko Health acquire certain assets of BioReference Health
Labcorp (LH) and OPKO Health (OPK) announced that they have entered into an agreement for Labcorp to acquire select assets of BioReference ...